Target Opportunity BPH treatment market tailwinds and large patient population present a sizable addressable market for minimally invasive solutions. Zenflow’s Spring System targets office-based, atraumatic procedures, aligning with growing demand for less invasive urology options and clear clinical need beyond drugs.

Clinical Validation Ongoing trials show positive results up to four years post-treatment, supporting long-term efficacy and safety. This can be leveraged to build credibility with hospitals, clinics, and reimbursement bodies when pursuing partnerships and market expansion.

Strategic Funding Recent Series C financing led by Cook Medical with continued support from top investors signals strong investor confidence and potential for accelerated sales execution, partnerships, and channel development in the US and international markets.

Expansion Readiness Presence of a growing clinical footprint and participation in major urology conferences indicates readiness for broader adoption. Leverage conference exposure and clinical data to drive KOL engagements, distributor partnerships, and hospital procurement conversations.

Competitive Positioning Compared to larger medical device players, Zenflow operates with a focused product in a sizable niche. Highlight the in-office procedure advantage, reduced risk of sexual side effects, and streamlined deployment to differentiate in sales pitches and ROI analyses for urology practices.